Navigation Links
First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

efits (e.g., improved patient outcomes) of therapies. Previous economic models made assumptions regarding the impact of IFN-(beta) on treatment effects (e.g., constant treatment effects over time) because of data limitations, which also made it difficult to examine the impact NAbs have on cost-effectiveness, as they may inhibit the effectiveness of IFN-(beta) treatment. The model used in the present analysis assumed that NAbs would impact the probability of relapse only after the second year of continuous interferon treatment and therefore potentially negatively affect treatment cost and outcomes for therapies susceptible to the development of NAbs.

"The development of NAbs have been shown to reduce the efficacy of IFN-(beta) therapies on magnetic resonance imaging (MRI) outcomes, relapse rate and disability progression, which in turn may affect the cost and outcomes associated with these therapies," Johnson said. "Although the results of this study provide decision makers with relevant data to evaluate the cost-effectiveness of immunomodulatory treatments versus symptom management in treating RRMS, it is important to consider the results in context, given that head-to-head randomized clinical trials comparing the immunomodulatory therapies are necessary to validate the projections from the pharmacoeconomic analyses."

About the Study

A literature-based Markov model was developed to estimate the economic outcomes of five treatment strategies: symptom management (e.g., physical therapy/exercise and pharmacological treatment) alone and symptom management combined with COPAXONE(R) (glatiramer acetate injection), IM-IFN(beta)1-a (Avonex(R)), SC-IFN(beta)1-a (Rebif(R)), or SC-IFN(beta)1-b (Betaseron(R)) in patients diagnosed with RRMS. This is the first economic model in MS to incorporate long-term data on treatment effects, account for differences among clinical trial designs of the immunomodulatory therapies and present the results in terms of cost-
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:10/17/2014)... -- Investor-Edge has initiated coverage on the ... ), NPS Pharmaceuticals Inc. (NASDAQ: NPSP ), ... Inc. (NASDAQ: MNTA ), and Catalyst Pharmaceutical ... companies can be accessed at: http://investor-edge.com/register . ... ended on a mixed note as the Dow Jones ...
(Date:10/17/2014)... -- Ameritox SM , the nation,s leader in medication monitoring ... , M.D., as Chief Medical Officer. In this role, ... for healthcare providers, patients and managed care plans.   ... variety of healthcare companies that have provided him with ... health sides of Ameritox,s business. He most recently served ...
(Date:10/17/2014)... ANGELES , Oct. 17, 2014 CytRx ... and development company specializing in oncology, announced that data ... aldoxorubicin for the treatment of first-line soft tissue sarcoma ... at the 2014 Connective Tissue Oncology Society (CTOS) Annual ... Berlin , Germany. Due to the longer ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Ameritox Appoints New Chief Medical Officer 2CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 2CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 3CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 4CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 5CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 6
... Inc. (OTC Bulletin Board: MCLN ), the leading ... and disposal of medical waste and the destruction of ... the 2010 second quarter for the period ended June 30, ... MedClean has addressed its capital requirements ...
... Group, Inc., (EHG), parent company of DentalXChange, a ... solutions for patients, payers and providers in the ... has selected DentalXChange as its latest Endorsed Program. ... members to receive an immediate savings on DentalXChange,s ...
Cached Medicine Technology:MedClean Technologies Announces Second Quarter Results 2MedClean Technologies Announces Second Quarter Results 3MedClean Technologies Announces Second Quarter Results 4MedClean Technologies Announces Second Quarter Results 5DentalXChange Endorsed by California Dental Association 2DentalXChange Endorsed by California Dental Association 3
(Date:10/20/2014)... 20, 2014 Punzoné , the first ... U.S., has a lot to celebrate this month. October marks ... the achievements and contributions of Americans of Italian heritage and ... and today it shares its favorite Italian cocktails and encourages ... Italy - even if it is only in a glass. ...
(Date:10/19/2014)... 2014 Recently, BambooIndustry.com, one of the ... new range of bamboo deckings . Moreover, the ... items; they are now available at deeply discounted rates. ... is hard to overstate the significance of online business ... online services. The company’s workers are striving to deliver ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Recently, Fancyflyingfox.com, ... special occasion clothes, has announced its latest designs of ... addition, all the new elegant outfits are offered with ... place an order before October 30 can enjoy this ... and great marketing strategies, it has become one of ...
(Date:10/19/2014)... systemic disease that causes inflammation in the spinal ... of the ancient Egyptian royal families. Now a ... , a journal of the American College of ... degenerative spinal condition called diffuse idiopathic skeletal hyperostosis ... to early 20th Dynasties. , Ankylosing spondylitis ...
(Date:10/19/2014)... DENVER (October 20, 2014) - As Alaska and ... outright legalization of recreational marijuana for adults, Ryan Fox ... those states and elsewhere in America: make sure your ... , Fox is founder and CEO of The Grass ... recreational dispensaries. , The Grass Station also gets ...
Breaking Medicine News(10 mins):Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2Health News:Cannabis CEO Warns Those States Considering a Legal Marijuana Market to Do Their Homework First 2Health News:Cannabis CEO Warns Those States Considering a Legal Marijuana Market to Do Their Homework First 3
... research has given hopes that researchers will be able to ... ears of humans challenged by deafness//. ,These tiny hairs in ... translated by the brain into sound. Once lost, these ... hearing loss. , ,Approximately, one out of every twenty-four people, ...
... have said that New Orleans seems to be going ... of an intensity rarely seen in the US. ... hurricane Katrina struck, 10 months ago. To make matters ... completely leaving the police department to deal with the ...
... on Thursday in favour of a group of South ... must immediately remove restrictions on free access to anti-retroviral ... case was brought on behalf of 15 inmates by ... Treatment Action Campaign stated that the prison authorities were ...
... join hands against HIV/AIDS and are set to discuss the ... ,Alarmed by the rising numbers of HIV/AIDS cases in the ... across party lines are to participate in a conference here ... the assembly speaker, said that over 300 legislators including 243 ...
... In a bid to upgrade tertiary healthcare infrastructure and ... institutions in the country// at a cost of Rs.15.6 ... taken at a meeting of the Cabinet Committee on ... an eye on underserved states like Jammu and Kashmir, ...
... to counter cholera epidemic which has killed about 2,000 people ... ,The UN health agency said it is sending drugs, oral ... and a shortage of safe drinking water, major vector of ... in most provinces, a daily incidence of around 125 cases ...
Cached Medicine News:Health News:Bihar Legislators Join Hands to Fight Against AIDS 2
... The AutoDELFIA Insulin kit is ... in serum and heparin plasma using ... assay is used in the investigation, ... hypoglycemia (low blood glucose level). The ...
ELISA for the detection of 17a OH Progesterone....
... accurate and stable storage conditions at ... the same alarm, monitoring and recording ... Labcold BS Blood bank range providing ... An independent 7 day circular chart ...
... Helmer PC1200 Platelet Incubators ... your laboratory counter top. These ... institution to have the security ... environment without taking up a ...
Medicine Products: